C-type natriuretic peptide engrafted antibodies

Patent metadata

Field	Value
Publication number	US-2025236654-A1
Application number	US-202418970421-A
Country	US
Kind code	A1
Filing date	Dec 5, 2024
Priority date	Apr 12, 2018
Publication date	Jul 24, 2025
Grant date	—

Abstract

The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a C-Type Natriuretic Peptide (CNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.

First claim

1 : An antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of an initial antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a C-Type Natriuretic Peptide (CNP) and a C-terminal linker sequence (Ctls), and
wherein: a) the amino acid stretch present between
i) amino acid residue HC res25 according to Kabat and the first amino acid residue of said CNP in case of an incorporation of said heterologous amino acid sequence within CDRH1,
ii) amino acid residue HC res51 according to Kabat and the first amino acid residue of said CNP in case of an incorporation of said heterologous amino acid sequence within CDRH2,
iii) amino acid residue HC res92 according to Kabat and the first amino acid residue of said CNP in case of an incorporation of said heterologous amino acid sequence within CDRH3,
iv) amino acid residue LC res26 according to Kabat and the first amino acid residue of said CNP in case of an incorporation of said heterologous amino acid sequence within CDRL1,
v) amino acid residue LC res49 according to Kabat and the first amino acid residue of said CNP in case of an incorporation of said heterologous amino acid sequence within CDRL2, and/or
vi) amino acid residue LC res88 according to Kabat and the first amino acid residue of said CNP in case of an incorporation of said heterologous amino acid sequence within CDRL3, is selected from the group consisting of the sequences of SEQ ID NOs: 443, 435, 439, or 440; and wherein: b) the amino acid stretch present between the last amino acid residue of said CNP and
i) amino acid residue HC res35a according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH1,
ii) amino acid residue HC res57 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH2,
iii) amino acid residue HC res106 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH3,
iv) amino acid residue LC res32 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL1,
v) amino acid residue LC res57 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL2, and/or
vi) amino acid residue LC res98 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL3,
is selected from the group consisting of the sequences of SEQ ID NOs: 434, 436, 437 or 441;
wherein said initial antibody is composed of two heavy chains having the sequence of SEQ ID NO: 65 and two light chains having the sequence of SEQ ID NO: 66 or 447; wherein said CNP is a human CNP; and wherein said fragment thereof is selected from the group consisting of Fab, Fab′, Fab′-SH, F(ab′)2, Fv fragments, diabodies, single domain antibodies (Dabs), linear antibodies, single-chain antibody molecules (scFv), and disulfide-stabilized Fv antibody fragments (dsFv).

2 : The antibody or fragment thereof according to claim 1 , wherein said CNP is a human CNP comprising the sequence of SEQ ID NO: 25.

3 - 8 . (canceled)

9 : The antibody or fragment thereof according to claim 1 , comprising at least one further natriuretic peptide.

10 : The antibody or fragment thereof according to claim 1 , wherein said antibody or fragment thereof is a human or humanized antibody or fragment thereof.

11 - 12 . (canceled)

13 : A composition comprising the antibody or fragment thereof according to claim 1 .

14 : A nucleic acid or a mixture of nucleic acids encoding the antibody or fragment thereof according to claim 1 .

15 : A host cell comprising the nucleic acid or the mixture of nucleic acids according to claim 14 .

16 : A process for producing an antibody or fragment thereof, comprising culturing the host cell according to claim 15 under conditions suitable for expression of the antibody or fragment thereof.

17 : A method of treating cardiovascular, renal, pulmonary, skeletal, ocular, thromboembolic or fibrotic diseases or disorders, dwarfism, achondroplasia or other cGMP-related and/or natriuretic peptide responsive disorders in an individual, comprising administering to the individual an effective amount of the antibody or fragment thereof according to claim 1 .

18 . (canceled)

19 : The antibody or fragment thereof of claim 1 , wherein at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein.

20 : The antibody or fragment thereof according to claim 9 , wherein said CNP and said at least one further natriuretic peptide are incorporated within at least two separate CDR regions.

21 : The antibody or fragment thereof according to claim 20 , wherein said at least one further natriuretic peptide is selected from the group consisting of ANP, BNP and CNP.

22 : The antibody or fragment thereof according to claim 21 , wherein said at least one further natriuretic peptide is selected from ANP and BNP.

23 : The antibody or fragment thereof according to claim 10 , wherein said antibody or fragment thereof is of the class IgG.

24 : The composition of claim 13 , further comprising a pharmaceutically acceptable carrier.

Assignees

• Bayer Ag

Inventors

• Brockschnieder Damian
• Hofmeister Lucas Hudson
• Noack Claudia
• Tebbe Jan
• Walsh Stuart
• Wilmen Andreas
• Wunder Frank

Classifications

• C07K2319/00

  Fusion polypeptide · CPC title

• C07K2318/10

  Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title